# A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.

> **NCT03507842** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Asan Medical Center** · enrollment: 380 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** High dose Cytarabine
- **DRUG:** Cytarabine
- **DRUG:** Hign dose Daunorubicin

## Key facts

- **NCT ID:** NCT03507842
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2018-03-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507842, "A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03507842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*